LYG1 exerts antitumor function through promoting the activation, proliferation, and function of CD4⁺ T cells.

ABSTRACT: Identification of novel stimulatory cytokines with antitumor function would have great value in tumor immunotherapy investigations. Here, we report LYG1 (Lysozyme G-like 1) identified through the strategy of Immunogenomics as a novel classical secretory protein with tumor-inhibiting function. LYG1 recombinant protein (rhLYG1) could significantly suppress the growth of B16 tumors in WT B6 mice, but not in SCID-beige mice, Rag1^-/- mice, CD4⁺- or CD8⁺ T cell-deleted mice. It could increase the number of CD4⁺ and CD8⁺ T cells in tumor-infiltrating lymphocytes, tumor-draining lymph nodes, and spleens, and promote IFNγ production by T cells in tumor-bearing mice. In vitro experiments demonstrated that rhLYG1 could directly enha

SUBMITTER: Liu H 

PROVIDER: S-EPMC5414861 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature